Treatment
5Allergic bronchopulmonary aspergillosis therapy reference (2026)
Reference snapshot of ABPA therapy across acute, recurrent, and emerging biologic-integrated tiers.
Severe COPD therapy reference (2026)
Reference snapshot of severe COPD therapy across foundational inhaler, biologic, and emerging mechanism tiers.
Obstructive sleep apnea therapy reference (2026)
Reference snapshot of OSA therapy across positive airway pressure, oral appliances, surgery, neurostimulation, and emerging pharmacotherapy.
Refractory chronic cough therapy reference (2026)
Reference snapshot of refractory chronic cough therapy across symptomatic, off-label, and emerging targeted tiers.
COPD pipeline expansion, 2026 mid-year reference
Reference layout of the COPD therapeutic pipeline as of mid-2026: established inhaled bronchodilator and inhaled corticosteroid combinations, the emerging biologic class (anti-IL-5, anti-IL-33, anti-TSLP), novel small-molecule mechanisms, and the live commercial questions across the pipeline.